Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Baochen Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Anti-Tumor Molecular Target Technology Innovation Center, Hebei Researc…. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 151 Literaturangaben. Gefördert von: Natural Science Foundation of Hebei Province, Hebei Normal University, Department of Education of Hebei Province.
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) comprise antibodies, cytotoxic payloads, and linkers, which can integrate the advantages of antibodies and small molecule drugs to achieve targeted cancer treatment. However, ADCs also have some shortcomings, such as non-negligible drug resistance, a low therapeutic index, and payload-related toxicity. Many studies have focused on changing the composition of ADCs, and some have even further extended the concept and types of targeted conjugated drugs by replacing the targeted antibodies in ADCs with peptides, revolutionarily introducing peptide-drug conjugates (PDCs). This Perspective summarizes the current research status of ADCs and PDCs and highlights the structural innovations of ADC components. In particular, PDCs are regarded as the next generation of potential targeted drugs after ADCs, and the current challenges of PDCs are analyzed. Our aim is to offer fresh insights for the efficient design and expedited development of innovative targeted conjugated drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Anti-Tumor Molecular Target Technology Innovation Center, Hebei Research Center of the Basic Discipline of Cell Biology, College of Life Scie…
- School of Chemical Technology, Shijiazhuang University, Shijiazhuang 050035, P.R. China.
ORCID-Profile: Yu Cheng
Förderung
- Natural Science Foundation of Hebei Province
- Hebei Normal University
- Department of Education of Hebei Province
- Science and Technology Project of Shijiazhuang Bureau
Zitieren
APA
Zhang, B., Wang, M., Sun, L., Liu, J., Yin, L., Xia, M., Zhang, L., Liu, X., & Cheng, Y. (2024). Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00106
Vancouver
Zhang B, Wang M, Sun L, Liu J, Yin L, Xia M, et al. Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00106
BibTeX
@article{Zhang2024,
author = {Zhang, Baochen and Wang, Mo and Sun, Li and Liu, Jiawei and Yin, Libinghan and Xia, Mingjing and Zhang, Ling and Liu, Xifu and Cheng, Yu},
title = {Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00106}
}
EUVIMED